QMS Medical Allied Services quarterly results

Q1 FY27 · Apr–Jun 2026
₹ croreQ1 FY27Q1 FY26Change
Revenue56.946.5+22.3%
EBITDA8.36.4+29.0%
EBITDA margin14.6%13.9%+0.8 pts
Profit before tax5.54.5+23.8%
Net profit4.06.3−37.3%
EPS₹2.05₹1.64+25.0%

Every quarter

₹ crore except per share
Tap a line for its trendQ1 FY27Jun 2026Q4 FY26Mar 2026Q3 FY26Dec 2025Q2 FY26Sep 2025Q1 FY26Jun 2025Q4 FY25Mar 2025
56.981.737.391.246.588.4
0.40.50.30.50.31.3
57.382.237.691.746.889.7
Expenses
30.145.324.454.827.843.7
−3.9−4.2−5.5−3.3−1.91.5
11.28.93.06.33.35.4
1.73.81.72.81.42.7
1.52.11.01.80.92.2
11.219.28.620.010.824.6
51.775.133.382.442.380.1
8.312.56.713.46.413.3
6.810.45.711.65.611.1
Profit
5.57.14.39.34.59.7
5.57.14.39.34.59.7
1.32.41.12.31.13.1
0.3−0.40.00.30.3−0.5
1.61.91.12.61.32.6
0.00.00.00.02.90.0
4.05.23.26.76.37.1
4.0—————
−0.0—————
3.9—————
3.6—————
0.3—————
Per share
₹2.05₹2.11₹1.24₹3.32₹1.64₹3.51
₹2.05₹2.11₹1.24₹3.32₹1.64₹3.51
Profit build-up — alternate / pre-Ind-AS tags
—7.14.39.34.59.7
———2.2——
—5.23.26.73.27.1
—0.00.00.00.20.0
Continuing & discontinued operations
—5.23.26.73.27.1
Other comprehensive income — detail
−0.0—————
−0.0—————
−0.0—————
3.6—————
0.3—————
Per share — as-filed variants
₹2.05—————
₹2.05—————
Derived — gross profit (revenue − materials − purchases − Δ inventories)
30.740.618.439.720.643.3
54.0%49.6%49.4%43.5%44.2%48.9%
Adjusted (ex-exceptional items) — derived
5.57.14.39.34.59.7
4.05.23.26.76.37.1
₹2.05₹2.11₹1.24₹3.32₹1.64₹3.51
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

QMSMEDI₹177.18

QMS Medical Allied Services Limited

· Pharma & Health
AnnualQuarterly₹ CroreMcap ₹343 Cr
View
In ₹ Crore except Per Share
3 Months Ending
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations88.446.591.237.381.756.9
Other Income1.30.30.50.30.50.4
Total Income89.746.891.737.682.257.3
Expenses
+ Purchases of Stock-in-Trade43.727.854.824.445.330.1
+ Changes in Inventories1.5-1.9-3.3-5.5-4.2-3.9
+ Employee Benefit Expense5.43.36.33.08.911.2
+ Finance Costs2.71.42.81.73.81.7
+ Depreciation & Amortisation2.20.91.81.02.11.5
+ Other Expenses24.610.820.08.619.211.2
Total Expenses80.142.382.433.375.151.7
EBITDA13.36.413.46.712.58.3
EBIT11.15.611.65.710.46.8
Profit
PBT before Exceptional Items9.74.59.34.37.15.5
Pretax Income9.74.59.34.37.15.5
+ Current Tax3.11.12.31.12.41.3
+ Deferred Tax-0.50.30.30.0-0.40.3
Tax Expense2.61.32.61.11.91.6
+ Share of Associates & JVs0.02.90.00.00.00.0
Net Income7.16.36.73.25.24.0
+ Net Income — Continuing Ops—————4.0
+ Other Comprehensive Income—————-0.0
Total Comprehensive Income—————3.9
Net Income to Common—————3.6
Minority Interest—————0.3
Per Share
Basic EPS3.511.643.321.242.112.05
Diluted EPS3.511.643.321.242.112.05
Profit Build-up — Alternate / Pre-Ind-AS Tags
PBT before Exceptional & Extraordinary Items9.74.59.34.37.1—
+ Adjustments to Profit / (Loss)——2.2———
Profit for the Period before Minority Interest7.13.26.73.25.2—
+ Minority Interest0.00.20.00.00.0—
Continuing & Discontinued Operations
Profit from Continuing Operations7.13.26.73.25.2—
Other Comprehensive Income — detail
+ Other Comprehensive Income—————-0.0
+ Items NOT to be Reclassified to P&L—————-0.0
+ Tax on Items NOT to be Reclassified—————-0.0
Comprehensive Income — Owners of Parent—————3.6
Comprehensive Income — Non-controlling Interests—————0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations—————2.05
Diluted EPS — Continuing Operations—————2.05
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit43.320.639.718.440.630.7
Gross Margin %48.9344.2343.5349.3749.6553.97
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)9.74.59.34.37.15.5
Net Income Adj (tax-effected)7.16.36.73.25.24.0
EPS Adj3.511.643.321.242.112.05
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.00
Filed Debt Equity—0.16—0.120.240.12
Filed Dscr—1.49—1.472.641.81
Filed Iscr—4.85—4.387.795.10
Paid Up Equity Capital17.9—19.319.319.319.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

QMS Medical Allied Services quarterly results

QMS Medical Allied Services (NSE: QMSMEDI) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹3.6 crore, down 42.1% from ₹6.3 crore in Q1 FY26 and down 29.7% from ₹5.2 crore in Q4 FY26. Revenue from operations was ₹56.9 crore, up 22.3% year on year and down 30.4% from the previous quarter.

Q2 FY26 results (a year earlier)
13 November 2025
Q1 FY27 results (the latest)
14 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by
14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit
₹3.6 Cr−42.1% vs Q1 FY26−29.7% vs Q4 FY26
Q1 FY27 revenue
₹56.9 Cr+22.3% vs Q1 FY26−30.4% vs Q4 FY26
Q1 FY27 operating margin
12.0%unchanged vs Q1 FY26−0.7 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier)
₹6.7 CrRevenue ₹91.2 Cr
Q1 FY27 EPS (basic)
₹2.05

Questions

When will QMS Medical Allied Services announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 13 November 2025.

What will QMS Medical Allied Services' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹6.7 crore and revenue from operations ₹91.2 crore. The latest quarter, Q1 FY27, had a net profit of ₹3.6 crore and revenue of ₹56.9 crore.

What were QMS Medical Allied Services' Q1 FY27 results?

Consolidated net profit was ₹3.6 crore, down 42.1% from ₹6.3 crore in Q1 FY26 and down 29.7% from ₹5.2 crore in Q4 FY26. Revenue from operations was ₹56.9 crore, up 22.3% year on year and down 30.4% from the previous quarter.

How has QMS Medical Allied Services' profit changed over the last four quarters?

Net profit by quarter: ₹6.7 crore in Q2 FY26, ₹3.2 crore in Q3 FY26, ₹5.2 crore in Q4 FY26 and ₹3.6 crore in Q1 FY27. That is ₹18.7 crore over the four quarters. Revenue from operations: ₹91.2 crore, ₹37.3 crore, ₹81.7 crore and ₹56.9 crore.

What was QMS Medical Allied Services' net profit in FY26?

Consolidated net profit was ₹11.9 crore in FY26 (April 2025–March 2026), down 13.0% from ₹13.7 crore in FY25.

What was QMS Medical Allied Services' revenue in FY26?

Revenue from operations was ₹173 crore in FY26 (April 2025–March 2026), up 10.8% from ₹156 crore in FY25.

Where do these QMS Medical Allied Services figures come from?

From QMS Medical Allied Services' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.